N/A
N=58
Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong
Gastric Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01679054 ↗Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcome: Primary: Expected and Unexpected Provider Costs — 2264.1; 522; 1135.7; 846 HK$
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vivian Wing Yan Lee
- Primary completion
- Jul 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Expected and Unexpected Provider Costs |
2264.1; 522; 1135.7; 846; 600; 9900 | — |
| SECONDARY Expected and Unexpected Societal Costs |
544; 1013.1; 402.7; 236.6; 3097.1; 2322.5 | — |
Summary
This is a retrospective cost-minimization analysis study to compare the costs of treatment with EOF vs EOX regimens in patients with gastric cancer (GC) in Hong Kong. Patient baseline characteristics and cost data will be extracted from records and compared.
Eligibility Criteria
Inclusion Criteria
- Patients who were diagnosed with gastric cancer and completed either EOX or EOF chemotherapy treatment
Exclusion Criteria
- Patients less than 18 years of age
- Patient who did not meet inclusion criteria
Data sourced from ClinicalTrials.gov (NCT01679054). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.